Is Sermorelin Legal in North Carolina?

What Sermorelin Is and How It Works

Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It tells your pituitary gland to secrete more of your own growth hormone (GH), rather than delivering exogenous GH directly. That physiological distinction matters legally and clinically.

Because sermorelin stimulates endogenous GH release rather than bypassing the axis entirely, it preserves the normal feedback loop. IGF-1 levels rise in response, but the pituitary can still down-regulate output if levels get too high. A 1997 placebo-controlled trial published in the Journal of the American Medical Association found that sermorelin significantly increased IGF-1 in adults with GH deficiency, which is the foundational evidence behind current clinical use.

Why Women's GH Physiology Differs

Women secrete GH in more frequent, lower-amplitude pulses than men across reproductive years. Estrogen amplifies pituitary sensitivity to GHRH, which means your GH axis is genuinely hormonally regulated in ways that differ from a man's. Research published in the Journal of Clinical Endocrinology and Metabolism confirms that estradiol increases GH pulse frequency and amplitude in premenopausal women, so any interpretation of your IGF-1 lab value must account for your hormonal status at the time of the draw.

How This Changes Across Life Stages

During reproductive years, GH output is highest in your late teens and gradually declines about 14 percent per decade after age 30. The FDA-approved prescribing information for sermorelin acetate notes that GH secretion declines with age in both sexes, but the rate of decline accelerates in women after menopause when estrogen drops sharply.

In perimenopause and post-menopause, falling estrogen reduces GHRH sensitivity, compounding the age-related GH decline. This is one reason some menopause clinicians look at IGF-1 alongside estradiol, FSH, and testosterone when evaluating body-composition changes, sleep quality, and fatigue in women over 40.

The Federal Legal Framework: Where Sermorelin Stands

Sermorelin's legal status flows almost entirely from federal FDA rules, not from any North Carolina-specific statute. Understanding the layers helps you ask the right questions of any clinic or compounding pharmacy.

FDA Approval History

Sermorelin acetate (brand name Geref) received FDA approval in 1997 for the diagnosis and treatment of GH deficiency in children. The FDA's approval record for Geref Diagnostic is publicly searchable in the drugs database. The manufacturer voluntarily withdrew the product from the US market in 2008, which is a commercial decision, not a safety withdrawal. That distinction is legally significant: the drug was not pulled for harm, and it is not scheduled under the Controlled Substances Act.

Because no brand-name sermorelin is currently marketed in the US, every sermorelin prescription filled today relies on compounding pharmacies. That is where federal law becomes the main concern.

The 503A and 503B Compounding Rules

The FDA divides compounding pharmacies into two categories under the Drug Quality and Security Act of 2013.

503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription. They must use bulk drug substances that appear on the FDA's list of substances that may be used in compounding, or that are components of FDA-approved drugs. Sermorelin is not on the current FDA 503A bulks list, which created a period of regulatory uncertainty starting around 2023 when the FDA began scrutinizing peptide compounding more aggressively.

503B outsourcing facilities operate at larger scale and can compound without individual patient prescriptions for office use. Sermorelin's status at 503B facilities follows the same underlying logic: it must meet FDA requirements for bulk substances.

The practical result is a three-tier check you should do before filling any sermorelin prescription:

1. Is the compounding pharmacy licensed in North Carolina and in the state where it physically operates?
2. Has the pharmacy documented compliance with FDA guidance on peptide bulk substances?
3. Does the pharmacy hold a valid state board registration (see below)?

A reputable compounding pharmacy will answer all three questions in writing. If a pharmacy cannot or will not, that is a meaningful warning sign regardless of what any clinic promises.

Is Sermorelin a Controlled Substance?

No. Sermorelin is not scheduled under the DEA Controlled Substances Act schedules, which means a prescriber does not need a DEA Schedule II-V authorization to prescribe it, and you do not need a triplicate prescription form. It is, however, a prescription-only drug under federal law, so no legitimate US source sells it over the counter or ships it directly to consumers without a clinician order.

North Carolina State Rules

North Carolina does not have a separate sermorelin-specific statute. Regulation happens through two bodies.

NC Board of Pharmacy

The North Carolina Board of Pharmacy licenses all pharmacies operating in the state and requires out-of-state compounding pharmacies that ship to North Carolina patients to hold a valid NC non-resident pharmacy permit. Before you fill a sermorelin prescription through a telehealth or mail-order pharmacy, you can verify the pharmacy's permit on the NC Board of Pharmacy online license lookup. This is a quick 60-second check that most women skip and should not.

NC Medical Board

The North Carolina Medical Board governs prescribing practices for licensed physicians and other mid-level providers in the state. Prescribing sermorelin off-label (for adult body composition, sleep, or anti-aging goals rather than diagnosed pediatric GH deficiency) is legally permitted under North Carolina's medical practice act, because off-label prescribing is a standard part of clinical medicine. The prescriber takes on professional responsibility for the clinical justification, which is why reputable clinics order baseline labs, including fasting IGF-1, before writing the prescription.

There is no North Carolina law that bans sermorelin for adults, restricts which specialty of clinician may prescribe it, or mandates a specific diagnostic threshold. What the Medical Board does require is that prescribing meet the standard of care for good medical practice, which in practice means documented clinical rationale and informed consent.

How to Get a Sermorelin Prescription in North Carolina

Getting sermorelin legally in North Carolina follows a defined pathway. Skipping any step puts you in a gray or illegal area.

Step 1: Lab Work First

A responsible prescriber will order at minimum a fasting IGF-1 (insulin-like growth factor 1) level, and usually a comprehensive metabolic panel, thyroid function tests, and a fasting insulin or HOMA-IR. For women, estradiol and FSH are relevant because low estrogen depresses IGF-1 independently of GH secretion. A 2002 study in Endocrinology demonstrated that estrogen replacement raised IGF-1 in postmenopausal women independently of GH status, which means a post-menopausal woman with low IGF-1 who is not on hormone therapy may have a different underlying cause than one who is.

If a clinic offers to prescribe sermorelin without any lab work, decline. Labs are not just bureaucratic boxes. They are the clinical basis that makes a prescription legal and safe.

Step 2: Telehealth vs. In-Person Consultation

Telehealth prescribing of sermorelin is legal in North Carolina for established clinician-patient relationships. The DEA's 2023 telehealth prescribing rules tightened requirements for controlled substances, but sermorelin is not a controlled substance, so those specific restrictions do not apply. The NC Medical Board's telehealth policy requires that the clinician obtain a complete medical history and that the clinical interaction be sufficient to establish a diagnosis, but it does not mandate an in-person visit for non-controlled substances.

Step 3: Pharmacy Verification

Once you have a prescription, confirm the pharmacy is:

• Licensed in North Carolina or holds an NC non-resident pharmacy permit
• A PCAB-accredited or state-board-inspected compounding facility
• Able to provide a Certificate of Analysis (COA) for each batch of sermorelin

The COA is the document that confirms potency, purity, and sterility testing. It is the single most important quality document for a compounded injectable peptide, because unlike a mass-manufactured drug, compounded products are not independently verified by the FDA before they reach you.

What You Can Expect to Pay

Because compounded sermorelin has no insurance billing code for adult off-label use, you will typically pay out of pocket. Prices vary widely: roughly $150 to $400 per month depending on dose, pharmacy, and whether a clinic administration fee is bundled. Be cautious of prices significantly below $150 per month, which may reflect low-quality compounding or an unregistered pharmacy.

Women-Specific Clinical Considerations

Reproductive Years (Ages 18-40)

In premenopausal women, the GH axis is actively modulated by the menstrual cycle. GH pulsatility peaks in the follicular phase when estradiol is rising. If you are getting IGF-1 tested to establish a baseline, ask your clinician to draw it in the early follicular phase (days 2-5 of your cycle) for the most consistent result.

PCOS complicates the picture. Women with PCOS often have insulin resistance, and research shows that hyperinsulinemia reduces GHRH receptor sensitivity, blunting the pituitary response to sermorelin. This does not mean sermorelin cannot be used in women with PCOS, but it does mean treating underlying insulin resistance first (metformin, lifestyle, or inositol supplementation) may be necessary before sermorelin produces a meaningful IGF-1 response.

Perimenopause (Roughly Ages 40-52)

This is the life stage where the intersection of declining estrogen and declining GH creates the most noticeable symptoms: disrupted sleep, shifting body composition toward central adiposity, reduced muscle recovery, and cognitive fog. A 2019 analysis in Menopause found that GH secretion was significantly lower in perimenopausal compared to premenopausal women even after controlling for age, which supports the clinical rationale some practitioners use for sermorelin in this population.

Whether hormone therapy (HT) should precede or accompany sermorelin in this group is an open clinical question. Estrogen replacement raises IGF-1 on its own, so starting HT first and re-checking IGF-1 before adding sermorelin is a reasonable approach.

Post-Menopause

Post-menopausal women have the lowest endogenous GH output of any adult female group. The evidence gap is significant here: most adult GH secretagogue trials enrolled mixed-sex cohorts with predominantly male participants, and female-specific efficacy and safety data are extrapolated rather than directly studied. Honest clinicians should say this plainly, and any clinic that overstates the certainty of outcomes in post-menopausal women is doing you a disservice.

Female-Specific Conditions to Discuss With Your Clinician

• PCOS: Insulin resistance blunts response; treat metabolic components first
• Endometriosis: No direct contraindication, but GH axis dysregulation has been reported in some endometriosis studies
• Female pattern hair loss: Some women use sermorelin partly for this indication; direct evidence is anecdotal
• Osteoporosis: GH plays a role in bone turnover; IGF-1 supports osteoblast activity, which is relevant in post-menopausal women with low bone mineral density, though sermorelin is not an approved osteoporosis therapy
• Hashimoto's thyroiditis and hypothyroidism: Untreated hypothyroidism suppresses GH secretion; thyroid function must be optimized before interpreting IGF-1 results

Pregnancy, Lactation, and Contraception

Sermorelin is contraindicated in pregnancy. There are no adequate, well-controlled human studies of sermorelin in pregnant women. Animal studies showing fetal harm at pharmacologic doses are the basis for the precautionary contraindication, and no regulatory body has established a safe dose in human pregnancy.

The FDA labeling for sermorelin acetate carries a pregnancy caution citing insufficient human data. Given that sermorelin stimulates GH and secondarily IGF-1, and that IGF-1 has direct mitogenic activity, the theoretical risk to a developing fetus is not trivial.

If you are trying to conceive, discuss this with your reproductive endocrinologist or OB-GYN before starting sermorelin. Some fertility-focused clinicians consider GH secretagogues in the context of poor ovarian response during IVF, but this is a specialist decision made with close monitoring, not a general telehealth prescription. ASRM guidelines acknowledge that adjuvant GH use in poor responders remains investigational and is not standard of care.

If you are sexually active and not using reliable contraception, your prescribing clinician should document this discussion and your contraception method before initiating sermorelin.

Lactation: There are no human data on sermorelin transfer into breast milk. The molecular weight of sermorelin (approximately 3,357 Da) suggests limited transfer, but because no safety data exist, most clinicians advise against use while breastfeeding. Discontinue sermorelin and consult your provider if you become pregnant while on therapy.

Who This Is Right For (and Who Should Wait)

Likely Appropriate Candidates

• Women over 35 with documented low-normal or low IGF-1 on repeated fasting labs
• Post-menopausal women with body-composition concerns not fully addressed by optimized HT
• Perimenopausal women with significant sleep disruption and fatigue after ruling out thyroid, anemia, and mood disorders
• Women with PCOS whose insulin resistance is well-controlled and whose IGF-1 remains low

Not the Right Fit Right Now

• Pregnant women or those actively trying to conceive without specialist fertility oversight
• Breastfeeding women (insufficient safety data)
• Women with active malignancy or a personal history of GH-sensitive cancers (IGF-1 is mitogenic)
• Women with uncontrolled hypothyroidism (the GH axis response will be blunted and results misleading)
• Women with active fluid retention, carpal tunnel syndrome, or edema (GH-axis stimulation can worsen these)
• Anyone who cannot access a pharmacy with documented COA testing for each batch

Side Effects Specific to Women

The most commonly reported side effects of sermorelin in clinical use are injection-site reactions, mild fluid retention, and transient morning grogginess. In women, two additional considerations are worth flagging.

First, because sermorelin is typically injected at bedtime to mirror the physiological nocturnal GH surge, women with insomnia may find that injection-site discomfort briefly worsens sleep onset. Starting at the low end of the dose range (200 mcg rather than 500 mcg) and titrating over 4-6 weeks reduces this.

Second, a small trial of GH secretagogues in women reported transient menstrual cycle lengthening in a subset of premenopausal participants, an effect that resolved after dose adjustment. Track your cycle length for the first three months of sermorelin use and report changes to your clinician.

What Honest Monitoring Looks Like

A legitimate sermorelin protocol includes follow-up labs at 8-12 weeks: repeat fasting IGF-1 to confirm the expected response, and a review of symptoms. The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults recommends titrating GH therapy to bring IGF-1 into the age- and sex-adjusted reference range, not to the top of the population range. The same principle applies to secretagogue therapy: the target is physiological normalization, not supraphysiological elevation.

For women, the IGF-1 reference range is age- and sex-adjusted, and laboratories differ in their reference intervals. Ask your clinician to use a lab range that accounts for menopausal status. Some commercial labs report a single adult female range, which misses the fact that a 55-year-old post-menopausal woman has a meaningfully different physiological IGF-1 set point than a 30-year-old in her luteal phase.